Cargando…

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation

Estrogen receptor alpha (ERα)-positive breast cancers are frequently treated with tamoxifen, but resistance is common. It remains elusive how tamoxifen resistance occurs and predictive biomarkers for treatment outcome are needed. Because most biomarker discovery studies are performed using pre-treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Severson, Tesa M., Nevedomskaya, Ekaterina, Peeters, Justine, Kuilman, Thomas, Krijgsman, Oscar, van Rossum, Annelot, Droog, Marjolein, Kim, Yongsoo, Koornstra, Rutger, Beumer, Inès, Glas, Annuska M., Peeper, Daniel, Wesseling, Jelle, Simon, Iris M., Wessels, Lodewyk, Linn, Sabine C., Zwart, Wilbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085127/ https://www.ncbi.nlm.nih.gov/pubmed/27129152 http://dx.doi.org/10.18632/oncotarget.8983

Ejemplares similares

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot
por: Beelen, Karin, et al.
Publicado: (2018)

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment
por: Beelen, Karin, et al.
Publicado: (2014)

A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
por: Zwart, Wilbert, et al.
Publicado: (2013)

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women
por: Joosten, Stacey E. P., et al.
Publicado: (2021)

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors
por: Singh, Abhishek A, et al.
Publicado: (2018)

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients
por: Beelen, Karin, et al.
Publicado: (2014)

Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2014)

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome
por: Schrijver, Willemijne, et al.
Publicado: (2018)

Integrative epigenetic taxonomy of primary prostate cancer
por: Stelloo, Suzan, et al.
Publicado: (2018)

CopywriteR: DNA copy number detection from off-target sequence data
por: Kuilman, Thomas, et al.
Publicado: (2015)

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo
por: Kim, Yongsoo, et al.
Publicado: (2019)

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
por: Severson, Tesa M., et al.
Publicado: (2017)

Phenotypic diversity drives paracrine drug tolerance
por: Kuilman, Thomas, et al.
Publicado: (2017)

Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2015)

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases
por: Severson, Tesa M., et al.
Publicado: (2021)

Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy
por: Schrijver, Willemijne A.M.E., et al.
Publicado: (2017)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Double-strand break toxicity is chromatin context independent
por: Friskes, Anoek, et al.
Publicado: (2022)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

Robust BRCA1‐like classification of copy number profiles of samples repeated across different datasets and platforms
por: Schouten, Philip C., et al.
Publicado: (2015)

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
por: Jager, Nynke GL, et al.
Publicado: (2013)

Androgen receptor profiling predicts prostate cancer outcome
por: Stelloo, Suzan, et al.
Publicado: (2015)

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer
por: Severson, Tesa, et al.
Publicado: (2022)

BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance
por: Kuilman, Midas M., et al.
Publicado: (2022)

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer
por: Severson, Tesa M., et al.
Publicado: (2018)

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts
por: Kemper, Kristel, et al.
Publicado: (2015)

CD4(+) T cell help creates memory CD8(+) T cells with innate and help-independent recall capacities
por: Ahrends, Tomasz, et al.
Publicado: (2019)

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance
por: Hoogstraat, Marlous, et al.
Publicado: (2022)

Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival
por: Iskit, Sedef, et al.
Publicado: (2015)

Molecular prediction of tamoxifen resistance in breast cancer
por: Kok, M, et al.
Publicado: (2005)

Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13
por: Bentin Toaldo, Cristiane, et al.
Publicado: (2015)

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
por: Almekinders, Mathilde M. M., et al.
Publicado: (2021)

Loss of androgen receptor signaling in prostate cancer‐associated fibroblasts (CAFs) promotes CCL2‐ and CXCL8‐mediated cancer cell migration
por: Cioni, Bianca, et al.
Publicado: (2018)

Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma
por: Theelen, W. S. M. E., et al.
Publicado: (2020)

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
por: Wolf, Denise M., et al.
Publicado: (2017)

A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers
por: In’t Veld, Sjors G. J. G., et al.
Publicado: (2017)

A breast cancer gene signature for indolent disease
por: Delahaye, Leonie J. M. J., et al.
Publicado: (2017)

Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer
por: Beumer, Inès J., et al.
Publicado: (2016)

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer
por: Kruger, Dinja T., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o5ih6pm6asqb33dvie401gond0